Bilateral phrenic nerve palsy induced by subcutaneous bortezomib in a patient with newly diagnosed multiple myeloma: first case reported.
作者信息
López Meritxell, Martínez Lacasa Xavier, Martí Josep M, Muntañola Ana, Fernández Mar, Huertas Sonia, Saumell Sílvia, De Diego Isabel, Bustamante Gabriela, Mesa Alba, Canet Marta, Julià Marta, Vall-Llovera Ferran
机构信息
a Department of Hematology , Hospital Universitari Mútua Terrassa , Terrassa , Spain.
b Department of Medicine , Hospital Universitari Mútua Terrassa , Terrassa , Spain.
出版信息
Leuk Lymphoma. 2017 Feb;58(2):482-484. doi: 10.1080/10428194.2016.1195496. Epub 2016 Jun 27.
Abstract
摘要
相似文献
1
Bilateral phrenic nerve palsy induced by subcutaneous bortezomib in a patient with newly diagnosed multiple myeloma: first case reported.
Leuk Lymphoma. 2017 Feb;58(2):482-484. doi: 10.1080/10428194.2016.1195496. Epub 2016 Jun 27.
2
Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial.
Haematologica. 2015 Jul;100(7):964-9. doi: 10.3324/haematol.2015.124347. Epub 2015 Apr 3.
3
Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial.
Haematologica. 2016 Dec;101(12):e485-e487. doi: 10.3324/haematol.2016.151266. Epub 2016 Aug 18.
4
Corneal sub-basal neural damage pattern in multiple myeloma patients treated with bortezomib: an in vivo confocal study.
Leuk Lymphoma. 2015;56(12):3440-1. doi: 10.3109/10428194.2015.1023723. Epub 2015 Jun 18.
5
Evaluation of Bortezomib-Induced Neuropathy Using Total Neuropathy Score (Reduced and Clinical Versions) and NCI CTCAE v4.0 in Newly Diagnosed Patients With Multiple Myeloma Receiving Bortezomib-Based Induction.
Clin Lymphoma Myeloma Leuk. 2017 Aug;17(8):513-519.e1. doi: 10.1016/j.clml.2017.06.035. Epub 2017 Jul 6.
6
Asymptomatic unilateral phrenic nerve palsy after bortezomib treatment in a newly diagnosed multiple myeloma patient.
J Oncol Pharm Pract. 2023 Mar;29(2):502-505. doi: 10.1177/10781552221112151. Epub 2022 Jul 3.
7
An acceptable incidence of infusion site reactions after subcutaneous bortezomib administration in the upper arm in Japanese patients with multiple myeloma.
Acta Haematol. 2015;133(1):29-30. doi: 10.1159/000362587. Epub 2014 Jul 1.
8
Assessment of bortezomib induced peripheral neuropathy in multiple myeloma by the reduced Total Neuropathy Score.
Leuk Lymphoma. 2014 Oct;55(10):2277-83. doi: 10.3109/10428194.2013.873535. Epub 2014 Mar 19.
9
The advantages of switch to subcutaneous bortezomib in the real life.
Leuk Lymphoma. 2018 Jun;59(6):1505-1507. doi: 10.1080/10428194.2017.1382695. Epub 2017 Oct 5.
10
Foot drop in patients treated with bortezomib - a case series and review of the literature.
Leuk Lymphoma. 2022 Mar;63(3):722-728. doi: 10.1080/10428194.2021.1992758. Epub 2021 Oct 26.
Zotero 插件